Mark J. Rosenblum

Filings by Mark J. Rosenblum span 3 companies, the busiest being Salarius Pharmaceuticals, Inc., Advaxis, Inc. and Hemobiotech Inc. The record holds 25 filings, for trades running from 4 March 2009 to 20 November 2025.

On the market, this insider has only ever bought: 7 purchases, €90k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 18 share grants. So far in 2025, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €4,695. On 4 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 20 November 2025: an open-market purchase of €14k, in Salarius Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.